Investment Rating - The report suggests a cautious investment outlook for the pharmaceutical and biotechnology sector, highlighting a slow recovery due to various factors such as price reductions from centralized procurement and healthcare cost control measures [2][12]. Core Insights - The overall performance of the pharmaceutical and biotechnology sector is under pressure, with a slight improvement in Q3 2025. The 452 listed companies in this sector reported a total revenue of CNY 1.85 trillion, a year-on-year decrease of 1.9%, and a net profit of CNY 140.6 billion, down 4.8% year-on-year [2][12]. - The sector's overall gross margin is at 30.87%, down 0.66 percentage points year-on-year, while the net margin is at 8.00%, down 0.28 percentage points year-on-year, indicating historically low profitability [2][29]. - There is significant performance differentiation among sub-sectors, with innovative drugs showing strong growth. The top five sub-sectors by revenue growth are innovative drugs (+23.34%), CXO (+12.36%), other biological products (+8.15%), upstream reagents (+6.11%), and pharmacies (+0.74%) [2][35]. Summary by Sections 1. Overall Industry Situation - The pharmaceutical manufacturing industry achieved a revenue of CNY 1.82 trillion in the first three quarters of 2025, a year-on-year decline of 2.00%, with total profits of CNY 253.48 billion, down 0.70% year-on-year [11][12]. - The industry's revenue and profit growth rates are significantly below the national industrial growth rate of 6.20% [11]. 2. Sub-sector Performance - The innovative drug sector continues to perform well, with a revenue increase of 23.34% and a net profit growth of 94.98% in Q3 2025 [2][35]. - The CXO sector also showed strong performance, with a revenue increase of 12.36% and a net profit increase of 55.90% [2][93]. - Other sub-sectors such as upstream reagents and pharmacies also reported positive growth, while traditional sectors like raw materials and vaccines faced significant declines [2][35][137]. 3. Company Recommendations - The report recommends focusing on investment opportunities in innovative drug chains, medical devices, healthcare services, second-class vaccines, chain pharmacies, traditional Chinese medicine, and raw materials [2]. 4. Market Trends - As of November 6, 2025, the pharmaceutical and biotechnology sector has seen an 18.61% increase, underperforming compared to the CSI 300 index [36]. - The sector's valuation is at a historical median level, with a PE ratio of 30.13, indicating a recovery from previous declines [41].

Market Overview - The Shanghai Composite Index closed at 4018.60 points, above the annual line, with a change of 0.53% [1] - The total trading volume of A-shares reached 2,194.371 billion yuan [1] Stocks Breaking Annual Line - A total of 112 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Shede Liquor: 9.90% - Binhai Energy: 8.36% - Pinwo Food: 6.38% [1] Detailed Stock Performance - The following table summarizes the performance of stocks that broke the annual line: - Shede Liquor (600702): Today's change of 10.01%, turnover rate of 7.58%, latest price 65.63 yuan [1] - Binhai Energy (000695): Today's change of 9.96%, turnover rate of 5.02%, latest price 12.47 yuan [1] - Pinwo Food (300892): Today's change of 8.84%, turnover rate of 16.98%, latest price 36.70 yuan [1] - Other notable stocks include: - Haida Co. (300320): 8.77% change, 9.19% turnover, latest price 10.91 yuan [1] - Huachao City A (000069): 9.92% change, 3.74% turnover, latest price 2.66 yuan [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that just crossed the annual line include: - Wanxin Media: Minor deviation rate [1] - Chengdu Bank: Minor deviation rate [1] - China Publishing: Minor deviation rate [1]

Core Viewpoint - Huaxia Eye Hospital (301267.SZ) has signed a supplementary agreement to extend the validity of the existing concerted action agreement by three years, until November 7, 2028, to maintain the stability of the company's governance structure and improve decision-making efficiency [1] Shareholding Structure - Mr. Su Qingcan, the chairman and general manager, directly holds 255,405,989 shares, accounting for 30.41% of the total shares [1] - Mr. Su Qingcan controls an additional 214,841,769 shares through an 84% stake in the largest shareholder, Huaxia Medical Investment (Xiamen) Co., Ltd., representing 25.58% of the total shares [1] - In total, Mr. Su Qingcan holds 470,247,758 shares, which is 55.98% of the total shares, through direct and indirect means [1] - Ms. Su Shihua is recognized as a concerted actor with Mr. Su Qingcan, and together they hold a total of 529,194,600 shares, accounting for 63.00% of the total shares [1]

Core Viewpoint - Huaxia Eye Hospital (301267.SZ) has signed a supplementary agreement to extend the validity of the existing concerted action agreement by three years, until November 7, 2028, to maintain the stability of its corporate governance structure and improve decision-making efficiency [1] Shareholding Structure - Mr. Su Qingcan, the chairman and general manager of the company, directly holds 255,405,989 shares, accounting for 30.41% of the total shares [1] - Through holding 84% of Huaxia Medical Investment (Xiamen) Co., Ltd., the largest shareholder, Mr. Su controls an additional 214,841,769 shares, representing 25.58% of the total shares [1] - In total, Mr. Su holds 470,247,758 shares, which is 55.98% of the total shares, either directly or indirectly [1] Concerted Action Agreement - Ms. Su Shihua is recognized as a concerted actor with Mr. Su Qingcan, and together they hold a total of 529,194,600 shares, which constitutes 63.00% of the total shares [1]

关于实际控制人及其一致行动人签署《一致行动协议之补充 协议》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司 华厦眼科医院集团股份有限公司（以下简称"公司"）于近日收到公司实际 控制人苏庆灿先生及其一致行动人苏世华女士通知，为保持公司治理结构的稳定 性，提高公司经营决策效率，苏庆灿先生与苏世华女士签署了《一致行动协议之 补充协议》，现将具体情况公告如下： 一、本次签署《一致行动协议之补充协议》的情况 苏庆灿先生与苏世华女士系兄妹关系，且根据苏庆灿先生与苏世华女士于 2017 年 1 月 1 日签署的《一致行动协议》，苏世华女士作为苏庆灿先生的一致 行动人，保证在行使股份表决权时与苏庆灿先生保持一致，且承诺未来持续履行 作为一致行动人在重大权益变动信息披露、要约收购（如适用）等方面的法定义 务。苏世华女士转让、质押其直接或间接持有的公司股份需取得苏庆灿先生的同 意。协议自双方签字后生效，有效期至公司完成首次公开发行股票并上市之日起 满 36 个月止。 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次 公开发行 ...

Core Viewpoint - The company, Huaxia Eye Hospital, has announced the lifting of restrictions on shares issued prior to its initial public offering (IPO), allowing for increased liquidity in the market [1][2]. Group 1: Share Structure and Restrictions - After the IPO, the total share capital of the company is 56 million shares, with 503,663,671 shares subject to trading restrictions, accounting for 89.94% of the total [1]. - As of the announcement date, the total share capital has increased to 84 million shares, with 511,171,125 shares under trading restrictions, representing 60.85% of the total [2]. - The lifting of restrictions involves 238,830,000 shares, which is 28.43% of the total share capital [2]. Group 2: Shareholder Information - The restricted shares are held by two shareholders, with a total of 511,170,000 shares, which is 60.85% of the total share capital [3][4]. - The major shareholders include Huaxia Medical Investment (Xiamen) Co., Ltd. and Su Qingcan, who is the chairman and general manager of the company [4]. Group 3: Financial Performance and IPO Details - The company raised a total of 305.28 million RMB from the IPO, with a net amount of 276.85 million RMB after deducting issuance costs [5]. - The original fundraising target was 77.85 million RMB, indicating a significant oversubscription of 198.99 million RMB [5]. - The company was listed on the Shenzhen Stock Exchange's ChiNext board on November 7, 2022, with an issue price of 50.88 RMB per share [5].

11月7日重点关注的财经要闻与资本市场大事： 今日看点 3、9家公司披露回购进展 11月7日，9家公司共发布9个股票回购相关进展。其中，1家公司首次披露股票回购预案，1家公司回购方案获股东大会通过，5家公司披露股票回购实施进 展，2家公司回购方案已实施完毕。 从首次披露回购预案来看，国瓷材料拟回购不超2.0亿元。从股东大会通过回购预案来看，苏豪时尚拟回购不超575.0万元。从回购实施进展来看，旗滨集 团、中集集团、宏润建设回购金额最高，分别回购1.96亿元、1.43亿元、1.37亿元。 4、美国10月失业率、美国10月季调后非农就业人口等数据将公布。 数据来源Wind，内容不构成任何投资建议） 1、中国10月进出口数据将公布 11月7日，海关总署将公布中国10月进出口等数据。 2、101.95亿元市值限售股今日解禁 11月7日，共有18家公司限售股解禁，合计解禁量为7.14亿股，按最新收盘价计算，合计解禁市值为101.95亿元。 从解禁量来看，5家公司解禁股数超千万股。华厦眼科、*ST围海、深中华A解禁量居前，解禁股数分别为3.2亿股、1.91亿股、1.38亿股。从解禁市值来看， 5家公司解禁股数超亿元。华厦 ...

每日经济新闻 从解禁市值来看，5家公司解禁股数超亿元。华厦眼科、深中华A、港迪技术解禁市值居前，解禁市值 分别为62.55亿元、9.19亿元、8.55亿元。 从解禁股数占总股本比例来看，5家公司解禁比例超10%。华厦眼科、耐科装备、港迪技术解禁比例居 前，解禁比例分别为38.05%、25.09%、20.82%。 每经AI快讯，Wind数据显示，周五（11月7日），共有18家公司限售股解禁，合计解禁量为7.14亿股， 按最新收盘价计算，合计解禁市值为101.95亿元。 从解禁量来看，5家公司解禁股数超千万股。华厦眼科、*ST围海、深中华A解禁量居前，解禁股数分别 为3.2亿股、1.91亿股、1.38亿股。 ...

Core Viewpoint - The company is actively engaging in domestic and international ophthalmology academic exchanges to advance clinical diagnosis and treatment techniques, education, and scientific research in the field of ophthalmology [1] Group 1 - The company has been hosting and participating in various ophthalmology academic exchange activities [1] - Several experts from the company hold key positions in the Cross-Strait Medical and Health Exchange Association's Ophthalmology Committee [1] - The company aims to leverage its geographical advantages to promote collaboration and integration within the ophthalmology industry across the Taiwan Strait [1]

Investment Rating - The report maintains a "Recommended" rating for Huaxia Eye Hospital (301267) with a target price of 23.05 yuan [2][8]. Core Views - The company's revenue for the first three quarters of 2025 reached 3.272 billion yuan, a year-on-year increase of 2.83%. The net profit attributable to the parent company was 434 million yuan, up 3.04% year-on-year [2][8]. - The revenue growth has slowed down due to industry environment and policy impacts, particularly the ongoing effects of cataract centralized procurement policies. However, the long-term growth logic in the consumer medical field remains intact, and revenue growth is expected to gradually recover as consumer demand rebounds [8]. - The company's gross margin for the first three quarters of 2025 was 45.03%, a decrease of 1 percentage point year-on-year, primarily due to the impact of cataract centralized procurement policies and a slowdown in high-margin consumer medical business growth [8]. - The company is actively exploring the application of cutting-edge technologies, such as smart glasses in ophthalmic medical services, which may open new application scenarios and business models [8]. - The forecasted net profits for 2025-2027 are 442 million, 484 million, and 549 million yuan, representing year-on-year growth of 3.2%, 9.4%, and 13.5% respectively [8]. Financial Summary - Total revenue for 2024 is projected at 4.027 billion yuan, with a growth rate of 0.3%. For 2025, revenue is expected to reach 4.192 billion yuan, reflecting a growth rate of 4.1% [4]. - The net profit attributable to the parent company is forecasted to be 429 million yuan in 2024, with a significant decline of 35.6%, followed by a recovery in subsequent years [4]. - The earnings per share (EPS) is expected to be 0.51 yuan in 2024, increasing to 0.65 yuan by 2027 [4].